2期试验中肿瘤大小的早期平均变化：有效终点还是虚假承诺？ - Suppr

Suppr

超能文献

Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?

作者信息

Rubinstein Larry V, Dancey Janet E, Korn Edward L, Smith Malcolm A, Wright John J

出版信息

J Natl Cancer Inst. 2007 Oct 3;99(19):1422-3. doi: 10.1093/jnci/djm167. Epub 2007 Sep 25.

DOI:10.1093/jnci/djm167

PMID:17895470

Abstract

摘要

相似文献

Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?

J Natl Cancer Inst. 2007 Oct 3;99(19):1422-3. doi: 10.1093/jnci/djm167. Epub 2007 Sep 25.

Newer phase II trial designs gaining ground.

J Natl Cancer Inst. 2007 Oct 3;99(19):1428-9. doi: 10.1093/jnci/djm182. Epub 2007 Sep 25.

Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group.

Eur J Cancer. 2011 Aug;47(12):1763-71. doi: 10.1016/j.ejca.2011.02.011. Epub 2011 Mar 22.

Optimising the design of phase II oncology trials: the importance of randomisation.

Eur J Cancer. 2009 Jan;45(2):275-80. doi: 10.1016/j.ejca.2008.10.029. Epub 2008 Dec 6.

Optimizing randomized phase II trials assessing tumor progression.

Contemp Clin Trials. 2007 Feb;28(2):146-52. doi: 10.1016/j.cct.2006.05.003. Epub 2006 May 19.

Design and endpoints of clinical trials in hepatocellular carcinoma.

J Natl Cancer Inst. 2008 May 21;100(10):698-711. doi: 10.1093/jnci/djn134. Epub 2008 May 13.

Improving the design of phase II trials of cytostatic anticancer agents.

Contemp Clin Trials. 2007 Feb;28(2):138-45. doi: 10.1016/j.cct.2006.05.009. Epub 2006 Jul 14.

Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.

J Natl Cancer Inst. 2007 Oct 3;99(19):1455-61. doi: 10.1093/jnci/djm158. Epub 2007 Sep 25.

Criticism of tumor response criteria raises trial design questions.

J Natl Cancer Inst. 2006 Feb 15;98(4):232-4. doi: 10.1093/jnci/djj086.

An efficient algorithm to determine the optimal two-stage randomized multinomial designs in oncology clinical trials.

J Biopharm Stat. 2011 Jan;21(1):56-65. doi: 10.1080/10543400903541097.

引用本文的文献

Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial.

J Natl Cancer Inst. 2024 May 8;116(5):673-680. doi: 10.1093/jnci/djae009.

Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation.

Clin Cancer Res. 2020 Dec 15;26(24):6464-6474. doi: 10.1158/1078-0432.CCR-20-1493. Epub 2020 Sep 28.

Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer.

BMC Cancer. 2014 Jan 4;14:5. doi: 10.1186/1471-2407-14-5.

Resampling phase III data to assess phase II trial designs and endpoints.

Clin Cancer Res. 2012 Apr 15;18(8):2309-15. doi: 10.1158/1078-0432.CCR-11-1815. Epub 2012 Jan 27.

The statistics of phase 0 trials.

Stat Med. 2010 May 10;29(10):1072-6. doi: 10.1002/sim.3840.

Melanoma: a model for testing new agents in combination therapies.

J Transl Med. 2010 Apr 20;8:38. doi: 10.1186/1479-5876-8-38.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验